Compare CIEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIEN | HALO |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 7.4B |
| IPO Year | 1997 | N/A |
| Metric | CIEN | HALO |
|---|---|---|
| Price | $233.00 | $68.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 12 |
| Target Price | ★ $219.29 | $73.33 |
| AVG Volume (30 Days) | ★ 3.8M | 2.6M |
| Earning Date | 12-11-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.55 | ★ 56.68 |
| EPS | 0.85 | ★ 4.74 |
| Revenue | ★ $4,769,507,000.00 | $1,242,852,000.00 |
| Revenue This Year | $17.66 | $34.83 |
| Revenue Next Year | $12.72 | $24.84 |
| P/E Ratio | $270.99 | ★ $14.22 |
| Revenue Growth | 18.79 | ★ 31.19 |
| 52 Week Low | $49.21 | $46.26 |
| 52 Week High | $248.00 | $79.50 |
| Indicator | CIEN | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 62.84 | 57.68 |
| Support Level | $201.70 | $61.23 |
| Resistance Level | $215.70 | $66.60 |
| Average True Range (ATR) | 12.53 | 2.08 |
| MACD | 0.70 | 0.50 |
| Stochastic Oscillator | 73.51 | 89.94 |
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.